Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Feb 08, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2011
> WALTHAM, Mass., Feb 01, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to
View HTML
Toggle Summary ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2011 Financial Results
-Company Expects Significant Progress across a Number of Programs in 2011-
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results WALTHAM, Mass., Jan 20, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (NASDAQ:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise
View HTML
Toggle Summary ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
WALTHAM, Mass., Jan 18, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the appointment of Theresa G.
View HTML